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Differences in Mitotic Activity May 
Explain Observed Differences in HIF-1α 
Response in Cancers and Stroma
Khush Mittal
I read the paper by Chi et al. with interest. The authors found 
a greater hypoxia response gene expression in carcinomas 
than stromal cells grown in vitro, but were not sure of 
the underlying explanation (see Discussion in [1]). The 
underlying explanation may be the difference in mitotic 
activity and hence metabolic activity between these two cell 
types, such that hypoxia may be present within cancer cells, 
although the surrounding culture media may have similar 
oxygen levels as the stromal cultures. 
The differences in mitotic activity could also explain 
greater hypoxia-related gene expression in clear-cell 
carcinoma compared with chromophobe carcinoma, normal 
tissue, or oncocytoma, as clear-cell carcinomas are more 
active mitotically. Did the authors compare the hypoxia gene 
expression with mitotic activity in various tumors? 
Khush Mittal (khush.mittal@med.nyu.edu)
New York University School of Medicine
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Borderline Thrombocytopenia or 
Mild Idiopathic Thrombocytopenic 
Purpura?
Jacques Zimmer, François Hentges, Emmanuel Andres
We read with interest the paper by Stasi et al. [1] about 
the follow-up of patients with a so-called borderline 
thrombocytopenia with platelet numbers of 100 × 109/l 
to 150 × 109/l. Data about the long-term outcome of such 
patients are indeed not frequent in the literature, as the 
authors claim, but some information has nevertheless 
previously been published, as in our retrospective study on 
adult idiopathic thrombocytopenic purpura (ITP) [2], not 
cited by Stasi et al. [1]. 
Our cohort was composed of 201 ITP patients separated 
by treated and untreated individuals. The latter group 
was composed of 62 patients (30.8% of the cohort) with a 
women/men sex ratio of 3.1/1 and a mean age of 39 years. 
The vast majority (54 patients, 87.1% of the untreated) 
were referred to the hospital because of mild isolated 
thrombocytopenia discovered on routine laboratory 
examination. These patients were asymptomatic and 
considered apparently healthy. In eight other cases (12.9%), 
however, a single, moderate, and spontaneously regressive 
bleeding episode occurred: purpura (n = 4), epistaxis (n 
= 1), gingivorrhagia after tooth extractions (n = 1), and 
meno- and metrorrhagia (n = 2) in two women with an 
intrauterine device and uterine polyps, respectively. The 
mean platelet count among these patients was 62 × 109/l, 
compared with 88 × 109/l for the entire untreated group. 
Antinuclear antibodies were tested in 46 cases (74.2%), 
with signiﬁ cantly positive values in six patients (13% of the 
tested individuals). During the follow-up period of 1.9 to 59 
months, no further bleeding occurred in the eight patients 
with initial moderate hemorrhage, although six of them 
remained thrombocytopenic for more than six months. None 
of the asymptomatic individuals developed any hemorrhagic 
symptoms. A chronic ITP (isolated thrombocytopenia 
of at least six months’ duration) was diagnosed in 31 
patients (59%) with a mean platelet count of 66 × 109/l. 
No autoimmune or hematological disease (other than 
ITP) developed in this group. Twenty-three patients were 
readdressed to their family physicians for further surveillance 
and lost to follow-up. 
According to current guidelines for the management of 
adult ITP [3,4], patients with platelet numbers >50 × 109/l are 
usually not treated. The stable and moderate evolution of the 
thrombocytopenia in our patients conﬁ rms the validity of this 
approach. The fact that we did not observe the development 
of other autoimmune diseases in contrast to the small 
number of such cases noticed by Stasi et al. [1] might be 
related to the smaller size of our cohort and/or the shorter 
follow-up period. As these authors deﬁ ne ITP as a persistent 
platelet count of less than 100 × 109/l and not 150 × 109/l as 
we did, a direct comparison of the results might be difﬁ cult. 
Whether a patient with platelet counts of less than 150 × 
109/l but more than 100 × 109/l is considered to have ITP or 
borderline thrombocytopenia is an academic question rather 
than a point of clinical importance, because the medical 
strategy is exactly the same (surveillance of platelet counts in 
the absence of any treatment). This holds true for patients 
with platelets between 50 × 109/l and 100 × 109/l that would 
be classiﬁ ed as ITP cases according to Stasi et al. [1]. Thus, 
it is not obvious why an additional clinical entity (borderline 
thrombocytopenia) should be created in addition to ITP. 
Jacques Zimmer (jacques.zimmer@crp-sante.lu)
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Authors’ Response to Zimmer et al.
We wish to thank Dr. Zimmer and colleagues [1] for critically 
reviewing our paper [2] and bringing to our knowledge their 
results. We partly agree with their comments, especially the 
part when they afﬁ rm that a direct comparison of the results 
is difﬁ cult. 
First of all, the design of the two investigations was 
different: ours was prospective and theirs was retrospective. 
Secondly, their data can hardly be interpreted and so cannot 
be a matter of contention. In fact, they merely report a mean 
platelet count of 88 × 109/l for the untreated group of 62 
idiopathic thrombocytopenic purpura patients and of 66 × 
109/l for the 31 patients later reclassiﬁ ed as having chronic 
idiopathic thrombocytopenic purpura. More importantly, 
they do not specify the number of their patients with a 
platelet count between 100 × 109/l and 150 × 109/l, i.e., the 
class of individuals that was the focus of our study. 
As an additional confounding factor, they report a follow-
up period of 1.9 to 59 months for the entire untreated 
group. If a median is not reported, this does not make much 
sense statistically. Theoretically, 31 patients might have been 
followed for 1.9 months, 30 patients for six months, and one 
single patient for 59 months. If this was the case, no wonder 
they did not observe a single case of autoimmune disease in 
their cohort. We do not share Dr. Zimmer’s point about a 
platelet count of 51 × 109/l to 100 × 109/l as equivalent to a 
higher count. Subjects who have a platelet count in the range 
of 50 × 109/l to 80 × 109/l are limited in their performance 
of particular physical jobs or traumatic activities such as 
contact sports. Besides, current guidelines suggest that a 
“safe” platelet count for major surgery, cesarean section, and 
spinal or epidural anesthesia should be at least 80 × 109/l 
[3]. Therefore, these patients may occasionally require an 
evaluation and possibly treatment that is not required for 
those with a borderline thrombocytopenia.
Finally, we deﬁ nitely rebut the issue of creating an 
unneeded clinical entity. The goal of our study was simply 
to describe the long-term outcome of individuals who were 
incidentally found with a platelet count between 101 × 109/l 
and 150 × 109/l. The terms “borderline thrombocytopenia” 
should be interpreted only as the deﬁ nition of a count in 
that range, not as a new clinical entity. In fact, we have 
clearly underlined that the majority of individuals will 
retain their borderline platelet count indeﬁ nitely without 
developing diseases. Only a prospective case-control study 
would establish whether such individuals have a higher 
risk of developing autoimmune disorders than the general 
population. Until then, these cases should be interpreted 
only as healthy individuals with a platelet count in the lower 
range of normal.  
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Schizophrenia Adoption Studies
Jonathan Leo
Patrick Sullivan cites twin and adoption studies as justiﬁ cation 
for searching for schizophrenia genes [1]. In his words, “Both 
adoption and twin studies indicate that the familiality of 
schizophrenia is due mainly to genetic effects.” To support 
this he provides a table (Table 1 in [1]) brieﬂ y summarizing 
these studies. Under “Adoption,” he mentions, “Adoptees 
with schizophrenia: increased risk in biological vs. adoptive 
parents (OR = 5.0; 95% CI 2.4–10.4).” However, rather 
than making a comparison between biological and adoptive 
parents, the original investigators made comparisons between 
index biological relatives and control biological relatives. 
In the schizophrenia literature three studies have used 
this design; the lead author of all three was Seymour Kety 
(1968, 1975, and 1994). All three studied people who grew 
up as adopted children and were later diagnosed with a 
“schizophrenia spectrum disorder.” The goal was to examine 
the rate of schizophrenia spectrum disorders among those 
August 2006  |  Volume 3  |  Issue 8  |  e362  |  e365  |  e366
PLoS Medicine  |  www.plosmedicine.org 1436
adoptees’ biological family members (with whom they did 
not grow up) and compare that rate to the rate among 
the biological relatives of control adoptees, who were not 
diagnosed with a schizophrenia spectrum disorder [2].
According to Kety himself, a comparison between index 
adoptees’ biological and adoptive relatives is “improper” and 
“fallacious” [3,4]. Indeed, in Kety’s ﬁ rst adoption study (1968) 
there was no signiﬁ cant elevation of chronic schizophrenia, 
or of schizophrenia spectrum disorders, among his index 
biological versus index adoptive relatives. (This is based on the 
data; the investigators did not make this comparison.) 
In addition, Kety and his colleagues did not limit 
themselves to looking at only parents. If they had done 
so, their conclusions would have been very different. For 
instance, in the 1975 study there were ﬁ ve index biological 
relatives diagnosed with chronic schizophrenia, but four of 
these ﬁ ve were half-siblings. The other diagnosis was given to 
a biological parent. In the 1968 Kety study, not a single index 
biological parent was diagnosed with chronic schizophrenia.
In his conclusion, Sullivan says that the treatment of the 
mentally ill mirrors the humanity of a society. True, but 
it then becomes difﬁ cult to rationalize the treatment of 
schizophrenia in this country in light of the World Health 
Organization studies showing that doctors in developing 
countries use less medication yet have a higher success rate 
than doctors in America. This is well documented in Robert 
Whitaker’s book Mad in America: Bad Medicine, Bad Science, and 
Enduring Mistreatment of the Mentally Ill [5]. 
Jonathan Leo (jonathan.leo@lmunet.edu)
Lincoln Memorial University
Harrogate, Tennessee, United States of America
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Author’s Response to Dr. Leo
Jonathan Leo raises issues with the adoption literature 
on schizophrenia [1]. These studies were intensively and 
independently scrutinized in the 1980s—see the series of 
papers by Kendler and Gruenberg (e.g., [2]). Most would 
agree that the number, size, and quality of adoption studies 
do not provide the highest-quality data (as discussed at more 
length elsewhere [3].
However, the salient point in my paper [4] was that this 
body of work (twin, adoption, and family studies) provides 
a consistent and solid rationale for the search for genes for 
schizophrenia. 
Dr. Leo’s comments about the treatment of schizophrenia 
are not within the scope of my paper. 
Patrick Sullivan (pfsulliv@med.unc.edu)
University of North Carolina
Chapel Hill, North Carolina, United States of America
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Telemedicine Complements Effective 
Health-Care Delivery but Is Not a 
Panacea
Rajiv Sarin
Like most health researchers in India, I share Sanjit Bagchi’s 
enthusiasm and optimism about the potential of telemedicine 
in improving health-care delivery in our diverse country [1]. 
However, it is important to maintain a balanced perspective 
and debunk overstatements such as those used by Bagchi 
in his conclusion “This potential was well summed up by 
Dr. Devi Shetty: ‘In terms of disease management, there is 
[a] 99% possibility that the person who is unwell does not 
require [an] operation. If you don’t operate you don’t need 
to touch the patient. And if you don’t need to touch the 
patient, you don’t need to be there. You can be anywhere, 
since the decision on healthcare management is based on 
history and interpretation of images and chemistry … so 
technically speaking, 99% of health-care problems can be 
managed by the doctors staying at a remote place—linked by 
telemedicine.’”
Maybe Devi Shetty, well known in telemedicine circles, has 
been quoted out of context, but it is not evident as such. In 
the wider context of the story, such conclusions as “If you 
don’t operate you don’t need to touch the patient”; “And 
if you don’t need to touch the patient, you don’t need to 
be there”; and “so technically speaking, 99% of health-care 
problems can be managed by the doctors staying at a remote 
place” are misleading. In the near future, online physicians or 
health professionals cannot replace the onsite ones for even 
30% of all health problems, let alone 99% as pointed out by 
Shetty. Even for providing essential and readily accessible 
health services, we need to augment the number of onsite 
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physicians and other health professionals with improved skill-
mix, more pragmatic public health policies, and enabling 
of telemedicine. Though India has been a pioneer in 
evaluating telemedicine for improving health-care delivery 
[2,3], its rightful place can be established only through major 
coordinated research efforts [4]. 
Free-access medical journals are a forum for debate 
on emerging health issues and have the responsibility to 
implement rigorous peer review and editorial control to 
prevent wide dissemination of any misleading statements 
or misquotes, as the case may be. Sweeping concluding 
statements from opinion leaders appearing in respectable 
journals may unduly inﬂ uence those lacking insight in the 
challenges of health-care delivery in underserved regions 
and allow further propagation by medical journalists living in 
virtual reality. 
To realize its full potential, we need to identify more 
innovative applications of telemedicine and generate 
robust data on its cost-effectiveness in different health-care 
settings [4]. But ﬁ rst we need changes in skill-mix [5], which 
includes enhancement of skills among various staff groups, 
role substitution between different groups, delegation up 
and down a uni-disciplinary ladder, and innovation in roles. 
Until we have telemedicine models that are universally 
implementable, with proven cost-effectiveness and user 
satisfaction [6], we need a stance of cautious optimism. 
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Further Advantages of a Unique 
Author Identiﬁ cation Number
Etienne Joly
I am in complete agreement with the suggestion by Matthew 
Falagas [1] that a unique author identiﬁ cation number 
(UAIN) would represent a major improvement for the 
use of databases of scientiﬁ c publications. In this regard, I 
perceive that he has not mentioned several other important 
advantages that a UAIN system would provide, and that are 
worth pointing to:
1. When looking up someone’s publications, the fact that 
the last name of a given person can vary from one paper to 
another can be as much of a problem as that of multiple 
authors with the same name. For example, these variations 
include women who change their last name after getting 
married (or divorced), middle initials that are sometimes 
included or omitted, translations from non-Roman alphabets 
that result in variable spellings, and people with last names 
composed of several terms that can sometimes appear in 
databases as split or truncated.
2. Contrarily to M. Falagas, I do not see any good reason 
why a UAIN system could not be retroactive. It is clearly in 
every scientist’s interest to facilitate the job of other people 
who want to look up their work. I therefore believe that 
authors could be asked to register for a UAIN, and to validate 
their list of publications themselves, retroactively. Even for 
the most productive scientists, this would take only a few 
minutes, and the fact that they had registered for a UAIN 
allowing users to trace their whole list of publications could 
then be indicated in the display of search results from the 
various bibliographic databases. I also do not see any reason 
for “hiding” this UAIN. I suggest that it could be designed 
to be quite simple to remember and to communicate to 
others, for example: the ﬁ rst four or ﬁ ve letters of the last 
name followed by the initial of the ﬁ rst name followed by the 
year of ﬁ rst scientiﬁ c publication followed by an incremental 
number depending on order of registration (my UAIN would 
be JOLY-E-89-01). It would therefore be something quite 
comparable in length and spirit to a car’s licence plate and, 
like UK licence plates, it would provide an interesting clue 
regarding the seniority of its bearer. 
3. This type of UAIN would therefore provide a very simple 
way to assess a person’s productivity. It would also provide a 
very useful means to assess the actual impact of their work in 
terms of citations, by discriminating between self-citation and 
citations by others.
Today, most people are evaluated via the impact factor of 
the journals in which they have managed to publish their 
work, and not by the actual impact of the papers themselves. 
Although most scientists acknowledge that this is an extremely 
crude and unfair way of assessing the quality of someone’s 
production, the impact factor lives on. By providing the simple 
means to track someone’s bibliographic record and thus 
facilitate the evaluation of their productivity, I believe that the 
introduction of a UAIN system will not only help the scientiﬁ c 
community to exploit bibliographic databases more efﬁ ciently, 
but also represent a major step towards getting rid of the 
despotic domination of the dreaded impact factors of journals 
as a means to evaluate the quality of scientiﬁ c papers. 
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Discussion Required for Correct 
Interpretation
Radek Bukowski, Gary D. V. Hankins, George R. Saade, 
Steve Thornton
Thank you for the opportunity to comment on the editorial 
by Romero and colleagues [1], which raises a number of 
important and interesting questions. Such discussion is 
mandatory if results of scientiﬁ c techniques such as gene 
array are to be correctly interpreted and used as the basis for 
future improvements in patient care.
It is interesting that re-analysis of our results does not 
demonstrate signiﬁ cant changes in gene expression and 
highlights the importance of the analysis technique in data 
interpretation. We agree with the editorial that there is a 
wealth of data that supports labour-associated changes in 
gene expression [2–5] and any implication that there are no 
signiﬁ cant labour-associated differences would ignore the 
results of numerous targeted analyses published by many 
independent researchers worldwide. Indeed the number 
and quality of such publications led us to make the basic 
assumption that there are labour-associated changes in 
gene expression. For this reason we calculated the p-value to 
identify those genes with the greatest difference in expression 
and smallest variability rather than to determine signiﬁ cance. 
This analytical design was strengthened by gene array analysis 
of each patient sample rather than analysis of pooled mRNA. 
We accept that there are a number of techniques available 
that can determine statistical signiﬁ cance whilst attempting to 
account for multiple analyses in gene array studies. However, 
those genes most likely to be important for the biological 
process of labour may or may not demonstrate a signiﬁ cant 
change in expression when corrections are made for multiple 
analyses. Furthermore, we have demonstrated that changes 
in the expression of individual genes are not independent, 
which complicates analysis. For example, the false discovery 
rate assumes a certain level of correlation among genes. 
However, the size of this correlation is not known and if 
underestimated can result in a high false negative rate. Thus, 
in keeping with other human uterine gene array data [6,7], 
we believe that there are likely to be important biological 
changes in labour-associated gene expression that may or 
may not be reﬂ ected by ﬁ nding statistical signiﬁ cance of 
a test chosen for analysis. We agree that the preparation 
(activation) of the uterus for the onset of labour is likely to 
occur in the weeks preceding its onset and such changes 
cannot be expected to be identiﬁ ed by labour and non-labour 
comparisons of gene expression.
Our original analysis included patient data, which was 
removed during re-analysis by Romero et al. Data from 
one patient were omitted because the arrays demonstrated 
saturation. A second set of data was removed because the 
modal probe intensity was 8-fold higher than the others. We 
normalised our data by transforming the expression value 
into a percentile and giving this as a multiple of the standard 
deviation (z-score). Thus, in contrast to some other methods 
of transformation (e.g., logarithmic), ours is insensitive to the 
magnitude of expression since genes are given a rank relative 
to other genes. Data from a third patient were removed 
because a different Affymetrix chip was used. We considered 
that inclusion of data from this chip was appropriate since 
it is almost identical to the original (all apart from 25 of the 
12,626 genes), and ranking genes by their z-scores removes 
chip-to-chip differences.
Our analysis identiﬁ ed genes that demonstrate a marked 
labour-associated difference in expression. We used this 
data to identify networks of genes that are co-regulated. 
We believe that the process of labour does not result from 
the independent expression of single genes but the effect 
of coordinated regulation of groups of genes that act in 
synchrony on a primed uterus to initiate labour. 
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